SAB BiotherapeuticsSABS +1.17%26 PB Ratio is 1.30 as of Jun. 25, 2026. GuruFocus rates SABS with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,233 Biotechnology companies, SAB Biotherapeutics ranks better than 76.32% on this metric.
The historical rank and industry rank for SAB Biotherapeutics's PB Ratio or its related term are showing as below:
SABS'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 1.32
Current: 1.3
During the past 7 years, SAB Biotherapeutics's highest PB Ratio was 1.32. The lowest was 0.00. And the median was 0.00.
SABS's PB Ratio is ranked better than 76.32% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs SABS: 1.30
During the past 12 months, SAB Biotherapeutics's average Book Value Per Share Growth Rate was 13.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -19.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -21.90% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of SAB Biotherapeutics was -11.50% per year. The lowest was -31.90% per year. And the median was -19.80% per year.
Back to Basics: PB Ratio
SAB Biotherapeutics (NAS:SABS) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
SAB Biotherapeutics PB Ratio Related Terms
SAB Biotherapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for SAB Biotherapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SAB Biotherapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SAB Biotherapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SAB Biotherapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where SAB Biotherapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
SAB Biotherapeutics (SABS) has a PB Ratio of 1.30 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on SAB Biotherapeutics and its competitors. According to the industry distribution chart, SAB Biotherapeutics ranks #292 out of 1233 companies in the Biotechnology industry, placing it in the top 23.7%.
Is SAB Biotherapeutics' PB Ratio too high?
SAB Biotherapeutics' current PB Ratio is 1.30. The Biotechnology industry median PB Ratio is 2.80. SAB Biotherapeutics' value of 1.30 is 53.6% below this industry median. Based on the distribution chart, SAB Biotherapeutics ranks #292 out of 1233 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SAB Biotherapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does SAB Biotherapeutics' PB Ratio compare to TRDA and ACIU?
According to the Biotechnology industry distribution chart, SAB Biotherapeutics ranks #292 out of 1233 companies for PB Ratio. This places SAB Biotherapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.80. SAB Biotherapeutics' value of 1.30 is 53.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SAB Biotherapeutics's current PB Ratio of 1.30 is 53.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on SAB Biotherapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SAB Biotherapeutics's current PB Ratio is 1.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SAB Biotherapeutics stock overvalued right now?
SAB Biotherapeutics (SABS) has a current PB Ratio of 1.30. The current PB Ratio is 1.30 and 53.6% below the Biotechnology industry median of 2.80. SAB Biotherapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For SAB Biotherapeutics (SABS), the current PB Ratio is 1.30 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
26GF Score
Get the complete analysis for SABS
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SABS has been successfully added to your 
